🇮🇹 Joining BioEurope Spring in Milan? Let’s connect! 🇮🇹 Alligator Bioscience AB's CEO, Søren Bregenholt, and CFO, Johan Gileus, are attending BioEurope Spring 2025, taking place 17–19 March in Milan, Italy. If you’re also in town, and eager to discuss our recently announced 24-month data for #mitazalimab in #mPDAC (follow the post link for the encouraging results 👉), reach out!
Om oss
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.
- Webbplats
-
https://www.alligatorbioscience.com
Extern länk för Alligator Bioscience AB
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Lund
- Typ
- Publikt aktiebolag
- Grundat
- 2001
- Specialistområden
- Immunotherapy of cancer, Immuno-oncology, CD40 och Combination therapy
Adresser
-
Primär
Få vägbeskrivning
Medicon Village
Lund, SE
Anställda på Alligator Bioscience AB
Uppdateringar
-
🚀 Encouraging 24-month survival data for mitazalimab in metastatic pancreatic cancer! Today we have released updated results from the Phase 2 OPTIMIZE-1 study, showing a 29.4% 24-month survival rate for mitazalimab + mFOLFIRINOX—triple that of chemotherapy alone. These results further reinforce mitazalimab’s potential as a durable and transformative treatment option for this aggressive disease. Key highlights: ✅ Median Overall Survival (mOS) of 14.9 months, outperforming historical benchmarks ✅ 6-month topline data from the 450 µg/kg cohort further supports 900 µg/kg as the Phase 3 dose ✅ Patients continue to show stable and encouraging survival outcomes over time With a confirmed regulatory path and strong clinical efficacy, Alligator Bioscience AB remain fully committed to advancing mitazalimab into Phase 3 and actively exploring strategic collaborations to maximize its impact. 🔗 Read the full press release by following the post link!
-
Brush up on your Swedish and register over at Redeye AB's to check out today's interview with Alligator Bioscience AB CFO Johan Gileus discussing the ongoing rights issue. 👉
-
Psst! 🐊 Check out Alligator Bioscience AB CEO Søren Bregenholt and CFO Johan Gileus joining BioStock - Connecting Innovation and Capital’s studio to discuss the ongoing rights issue. 👉
Alligator Bioscience AB utvecklar CD40-terapier för svårbehandlade cancersjukdomar. Bolaget är just nu aktuellt med en företrädesemission om cirka 280 Mkr som ska ta den ledande kandidaten mitazalimab till fas III och ett partnerskap. Vd Søren Bregenholt och CFO Johan Gileus besökte BioStocks studio för att diskutera detta. #AlligatorBioscience #BioStockSwe
-
🚀 Exciting News! The Nordic Business Diversity Index 2025 is out, and Alligator Bioscience AB made it again! A big congrats to all the top-performing small-cap companies across Helsinki, Stockholm, Copenhagen, and Oslo for leading the way in board and executive diversity. 🎉👏 Curious to dive into the findings? The full report is linked in the comments! ⬇️
The Nordic Business Diversity Index 2025 has been published. Congratulations for the top performing small-cap companies listed in Helsinki, Stockholm, Copenhagen and Oslo. Helsinki Exel Composites Solteq Plc Martela Group Biohit Oyj Boreo Plc Nurminen Logistics ORTHEX Lamor Apetit Oyj Endomines Ilkka Enersense International Oyj Honkarakenne Stockholm: Ascelia Pharma AB Dedicare AB Alligator Bioscience AB Abliva AB Mendus AB Pierce Group - Riders in Ecommerce Oncopeptides AB (publ) Karnell Group AB Bulten Group Ovzon Q-linea Nelly.com Copenhagen: Harboes Bryggeri BioPorto Diagnostics A/S GrønlandsBANKEN TCM Group Fynske Bank Pharma Equity Group A/S Rovsing A/S Asetek Shape Robotics Park Street A/S Djurslands Bank Kreditbanken Aquaporin Columbus Firstfarms Oslo: Goodtech Prosafe Gentian Diagnostics Otovo NRC Group Norge Gyldendal Norsk Forlag Tekna Holding Carasent Group Nekkar Capsol Technologies ASA Komplett Group Atlantic Sapphire Bien Sparebank ASA Congratulations to these top performing companies on the Nordic Business Diversity Index 2025! The 2025 edition of the Nordic Business Diversity Index by Impaktly studied over 10,000 board and executive members from over 840 companies listed across all Nordic markets. The link to the full Nordic Business Diversity Index 2025 report is in the comments below.
-
-
Check out today's BioStock - Connecting Innovation and Capital interview with Alligator Bioscience AB CEO Søren Bregenholt, discussing the recently announced cost-saving program, mitazalimab’s clinical data, and Alligator's efforts to achieve a partnership for our lead candidate! 👉
Alligator's CEO: "I'm confident that we will strike a deal"
https://www.youtube.com/
-
Psst! Check out today's PR 👉 https://lnkd.in/d5Se2WNA from the mitazalimab presentation at ASCO GI 2025, just this weekend! ✅ Indirect Comparison shows significant improvement of OS of mitazalimab + mFOLFIRINOX, compared to known FOLFIRINOX and NALIRIFOX outcomes ✅ The data substantiates the potential of this regimen in the context of the upcoming randomized Phase 3 trial
-
Psst! Out now - Alligator's Year-end report for 2024. And don't miss our call this afternoon at 3 pm CET, where you can pose any questions you might have to CEO Søren Bregenholt and CFO Johan Gileus. Register through the following link: 👉 https://lnkd.in/dZHfA4Dn Questions can also be e-mailed in advance to [email protected]
-
Exciting News from Alligator Bioscience AB! 🐊 Today we are thrilled to announce positive outcome of our regulatory interactions regarding the CMC development of #mitazalimab! As our CEO, Søren Bregenholt, puts it: "This regulatory feedback from both the FDA and PEI demonstrates the robustness of our CMC development strategy and validates the significant progress we’ve made in advancing mitazalimab towards Phase 3. We are confident in our ability to continue to execute on our timeline and bring mitazalimab one step closer to addressing the urgent unmet need for patients with metastatic pancreatic cancer." Follow the post link to check out today's PR.
-
📢 Register now for Alligator Bioscience AB's Year-end 2024 Earnings Call! 📢 We are excited to invite investors, analysts, and media to our upcoming earnings call on Wednesday, January 22, 2025, at 3:00 PM CET. Our CEO, Søren Bregenholt, and CFO, Johan Gileus, will present and comment on the Year-end report for 2024, followed by a Q&A session. This is a great opportunity to gain insights into our latest developments and future plans. 🗓 Event Details: Date: Wednesday, January 22, 2025 Time: 3:00 PM CET Language: English 📄 The Year-end report will be published on Wednesday, January 22, 2025 at 8:00 AM CET. 🔗 Register here to join the call: https://lnkd.in/dZHfA4Dn We look forward to your participation!
Liknande sidor
Finansiering
Alligator Bioscience AB
1 runda totalt
Se mer info på crunchbase
Senaste finansieringsrunda
Okänd serie
Extern Crunchbase Link för sista finansieringsrundan
7 426 017,00 US$